Primary Biliary Cirrhosis - Pipeline Review, H1 2019
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Primary Biliary Cirrhosis - Pipeline Review, H1 2019
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2019, provides an overview of the Primary Biliary Cirrhosis (Gastrointestinal) pipeline landscape.
Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 2, 11, 3, 1, 2 and 1 respectively.
Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2019, provides an overview of the Primary Biliary Cirrhosis (Gastrointestinal) pipeline landscape.
Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 2, 11, 3, 1, 2 and 1 respectively.
Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
TABLE OF CONTENTS
Introduction
Primary Biliary Cirrhosis - Overview
Primary Biliary Cirrhosis - Therapeutics Development
Primary Biliary Cirrhosis - Therapeutics Assessment
Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development
Primary Biliary Cirrhosis - Drug Profiles
Primary Biliary Cirrhosis - Dormant Projects
Primary Biliary Cirrhosis - Product Development Milestones
Appendix
List Of Tables
Number of Products under Development for Primary Biliary Cirrhosis, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Primary Biliary Cirrhosis - Pipeline by Albireo Pharma Inc, H1 2019
Primary Biliary Cirrhosis - Pipeline by Allergan Plc, H1 2019
Primary Biliary Cirrhosis - Pipeline by Arena Pharmaceuticals Inc, H1 2019
Primary Biliary Cirrhosis - Pipeline by Biocad, H1 2019
Primary Biliary Cirrhosis - Pipeline by Cadila Healthcare Ltd, H1 2019
Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics Inc, H1 2019
Primary Biliary Cirrhosis - Pipeline by Dr. Falk Pharma GmbH, H1 2019
Primary Biliary Cirrhosis - Pipeline by Eli Lilly and Co, H1 2019
Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals Inc, H1 2019
Primary Biliary Cirrhosis - Pipeline by Genfit SA, H1 2019
Primary Biliary Cirrhosis - Pipeline by GenKyoTex SA, H1 2019
Primary Biliary Cirrhosis - Pipeline by Gilead Sciences Inc, H1 2019
Primary Biliary Cirrhosis - Pipeline by Kowa Co Ltd, H1 2019
Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, H1 2019
Primary Biliary Cirrhosis - Pipeline by Novartis AG, H1 2019
Primary Biliary Cirrhosis - Pipeline by Tiziana Life Sciences Plc, H1 2019
Primary Biliary Cirrhosis - Pipeline by Virobay Inc, H1 2019
Primary Biliary Cirrhosis - Dormant Projects, H1 2019
List Of Figures
Number of Products under Development for Primary Biliary Cirrhosis, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
RELATED REPORTS
Primary Ciliary Dyskinesia - Pipeline Insight, 2021
DelveInsights, Primary Ciliary Dyskinesia Pipeline Insight, 2021, report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Primary Ciliary Dyskinesia pipeline landscape. It covers the pipeline drug
View ReportPrimary Immune Deficiency (PID) (Genitourinary Disorders) - Drugs In Development, 2021
Primary Immune Deficiency (PID) (Genitourinary Disorders) - Drugs In Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) (Genitourinary Disorders) - Drugs In Development,
View ReportGlobal Primary Biliary Cholangitis Treatment Market Research Report 2021-2025
In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Primary Biliary Cholangitis Treatment Report by Material, Application,
View ReportPrimary Biliary Cholangitis (Primary Biliary Cirrhosis) Global Clinical Trials Review, H2, 2020
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Global Clinical Trials Review, H2, 2020Its clinical trial report, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Global Clinical Trials Review, H2, 2020 provides an overview
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
